当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2007年第27期
编号:11506274
缺血性脑卒中神经保护剂联合治疗的研究进展(2)
http://www.100md.com 2007年9月25日 《中国医药导报》 2007年第27期
     [参考文献]

    [1]DeGraba TJ,Pettigrew LC.Why do neuroprotective drugs work in animals but not humans[J].Neurol Clin,2000, 18(2):475-493.

    [2]Fisher M, Bogousslavsky J. Further evolution toward effective therapy for acute is chemic stroke[J].JAMA, 1998, 279:1298-1303.

    [3]Grotta JC. Acute stroke therapy at the millennium: consummating the marriage between the laboratory and the besides[J].The Feinberg Lectu-re Stroke,1999,30(8):1722-1728.

    [4]Strauss WE,Thies WH,Robertson RM,et al.Fighting heart disease and stroke.Recommendations of the AHA stroke positioning taskforce.Stroke,1998,29(6):1272-1273.

    [5]Stroke Therapy Academic Industry Roundtable(STAIR). Recommen -dations for standards regarding preclinical neuroprotective and restortive drug development[J]. Stroke,1999,30:2752-2759.

    [6]Ma J,Endres M,Moskowitz MA.Synergistic effects of caspase inhibitors and MK-801 in brain injury after transient focal cerebral ischaemia in mice[J].Br J Pharmacol,1998, 124(4):756-762.

    [7]Hick CA,WardMA,Swettenham JB,et al.Synergistic neuroprotective effects by combining a NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischemia[J].Eur J Pharmacol 1999, 381(2-3):113-119.

    [8]Richard Liniger,RobertPopovic,BreandanSullivan, et al. Effect of neuroprotective cocktails on hippocampal neuron death in an invitro model of cerebral ischemia[J].J Neurosurg Anesthesiology, 2001,13(1): 19-25.

    (收稿日期:2007-08-20), 百拇医药(卞永禄 沈达涛 吴炳泉)
上一页1 2